Detalles de la búsqueda
1.
Prototype Pathogens for Vaccine and Monoclonal Antibody Countermeasure Development: NIAID Workshop Process and Outcomes for Viral Families of Pandemic Potential.
J Infect Dis
; 228(Suppl 6): S355-S358, 2023 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37849398
2.
Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness.
J Infect Dis
; 227(12): 1433-1441, 2023 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35876700
3.
Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses.
Clin Immunol
; 153(2): 308-22, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24907411
4.
Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS.
J Virol
; 87(6): 3526-37, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23325679
5.
NK and CD4+ T cell cooperative immune responses correlate with control of disease in a macaque simian immunodeficiency virus infection model.
J Immunol
; 189(4): 1878-85, 2012 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22798665
6.
Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge.
J Virol
; 86(8): 4644-57, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22345466
7.
Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy.
J Virol
; 85(2): 1099-116, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21068249
8.
Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
J Virol
; 84(14): 7161-73, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20444898
9.
Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge.
J Virol
; 82(21): 10911-21, 2008 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-18753198
10.
A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity.
J Immunol Methods
; 308(1-2): 53-67, 2006 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-16343526
11.
Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE.
Viral Immunol
; 18(1): 236-43, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-15802969
12.
Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef.
DNA Cell Biol
; 21(9): 627-35, 2002 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12396605
13.
Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route.
Clin Vaccine Immunol
; 19(5): 629-37, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22441384
14.
Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia.
Vaccine
; 29(17): 3310-9, 2011 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-21382487
15.
Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory.
Vaccine
; 29(35): 6017-28, 2011 Aug 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-21708207
16.
Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge.
Virology
; 411(1): 87-102, 2011 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21237474
17.
Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.
Expert Opin Biol Ther
; 8(9): 1347-63, 2008 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-18694354
18.
Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques.
Virology
; 374(2): 322-37, 2008 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-18252262
19.
Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.
Vaccine
; 26(26): 3312-21, 2008 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-18486283
20.
A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
J Virol
; 81(7): 3414-27, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17229693